Targeting glycosphingolipids for cancer immunotherapy.
Antibodies, Monoclonal
/ pharmacology
Antigens, Tumor-Associated, Carbohydrate
/ metabolism
Antineoplastic Agents, Immunological
/ pharmacology
Clinical Trials as Topic
Gangliosides
/ metabolism
Gene Expression Regulation, Neoplastic
/ drug effects
Glycosphingolipids
/ metabolism
Humans
Immunotherapy
Neoplasms, Glandular and Epithelial
/ drug therapy
Neuroectodermal Tumors
/ drug therapy
Tumor Microenvironment
/ drug effects
GD2
Gb5
Globo H
angiogenesis
glycosphingolipids
immunotherapeutics
Journal
FEBS letters
ISSN: 1873-3468
Titre abrégé: FEBS Lett
Pays: England
ID NLM: 0155157
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
02
07
2020
revised:
20
08
2020
accepted:
20
08
2020
pubmed:
30
8
2020
medline:
27
5
2021
entrez:
30
8
2020
Statut:
ppublish
Résumé
Aberrant expression of glycosphingolipids (GSLs) is a unique feature of cancer and stromal cells in tumor microenvironments. Although the impact of GSLs on tumor progression remains largely unclear, anticancer immunotherapies directed against GSLs are attracting growing attention. Here, we focus on GD2, a disialoganglioside expressed in tumors of neuroectodermal origin, and Globo H ceramide (GHCer), the most prevalent cancer-associated GSL overexpressed in a variety of epithelial cancers. We first summarize recent advances on our understanding of GD2 and GHCer biology and then discuss the clinical development of the first immunotherapeutic agent targeting a glycolipid, the GD2-specific antibody dinutuximab, its approved indications, and new strategies to improve its efficacy for neuroblastoma. Next, we review ongoing clinical trials on Globo H-targeted immunotherapeutics. We end with highlighting how these studies provide sound scientific rationales for targeting GSLs in cancer and may facilitate a rational design of new GSL-targeted anticancer therapeutics.
Identifiants
pubmed: 32860713
doi: 10.1002/1873-3468.13917
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antigens, Tumor-Associated, Carbohydrate
0
Antineoplastic Agents, Immunological
0
Gangliosides
0
Globo-H
0
Glycosphingolipids
0
sialogangliosides
0
dinutuximab
7SQY4ZUD30
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3602-3618Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Russo D, Capolupo L, Loomba JS, Sticco L and D'Angelo G (2018) Glycosphingolipid metabolism in cell fate specification. J Cell Sci 131, jcs219204.
Zhuo D, Li X and Guan F (2018) Biological roles of aberrantly expressed glycosphingolipids and related enzymes in human cancer development and progression. Front Physiol 9, 466.
Zhang T, de Waard AA, Wuhrer M and Spaapen RM (2019) The role of glycosphingolipids in immune cell functions. Front Immunol 10, 90.
Soliman C, Chua JX, Vankemmelbeke M, McIntosh RS, Guy AJ, Spendlove I, Durrant LG and Ramsland PA (2020) The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody. J Biol Chem 295, 1009-1020.
Liang YJ, Kuo HH, Lin CH, Chen YY, Yang BC, Cheng YY, Yu AL, Khoo KH and Yu J (2010) Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation. Proc Natl Acad Sci USA 107, 22564-22569.
Liang YJ, Yang BC, Chen JM, Lin YH, Huang CL, Cheng YY, Hsu CY, Khoo KH, Shen CN and Yu J (2011) Changes in glycosphingolipid composition during differentiation of human embryonic stem cells to ectodermal or endodermal lineages. Stem Cells 29, 1995-2004.
Chang WW, Lee CH, Lee P, Lin J, Hsu CW, Hung JT, Lin JJ, Yu JC, Shao LE, Yu J et al. (2008) Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyltransferases 1 and 2 in Globo H synthesis. Proc Natl Acad Sci USA 105, 11667-11672.
Ho MY, Yu AL and Yu J (2017) Glycosphingolipid dynamics in human embryonic stem cell and cancer: their characterization and biomedical implications. Glycoconj J 34, 765-777.
Kuo HH, Lin RJ, Hung JT, Hsieh CB, Hung TH, Lo FY, Ho MY, Yeh CT, Huang YL, Yu J et al. (2017) High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma. Sci Rep 7, 10750.
Lou YW, Wang PY, Yeh SC, Chuang PK, Li ST, Wu CY, Khoo KH, Hsiao M, Hsu TL and Wong CH (2014) Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers. Proc Natl Acad Sci USA 111, 2482-2487.
Yu AL, Hung JT, Ho MY and Yu J (2016) Alterations of glycosphingolipids in embryonic stem cell differentiation and development of glycan-targeting cancer immunotherapy. Stem Cells Dev 25, 1532-1548.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363, 1324-1334.
Ladisch S, Becker H and Ulsh L (1992) Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim Biophys Acta 1125, 180-188.
Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT and Barksdale EM Jr (2001) Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61, 363-369.
Handa K and Hakomori SI (2017) Changes of glycoconjugate expression profiles during early development. Glycoconj J 34, 693-699.
Huang C-S, Yu AL, Tseng L-M, Chow LWC, Hou M-F, Hurvitz SA, Schwab RB, Wong C-H, Murray JL, Chang H-K et al. (2016) Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer. J Clin Oncol 34, 1003.
Cheng JY, Wang SH, Lin J, Tsai YC, Yu J, Wu JC, Hung JT, Lin JJ, Wu YY, Yeh KT et al. (2014) Globo-H ceramide shed from cancer cells triggers translin-associated factor X-dependent angiogenesis. Cancer Res 74, 6856-6866.
Tsai YC, Huang JR, Cheng JY, Lin JJ, Hung JT, Wu YY, Yeh KT and Yu AL (2013) A prevalent cancer associated glycan, globo H ceramide, induces immunosuppression by reducing notch1 signaling. J Cancer Sci Ther 5, 264-270.
Kannagi R, Levery SB, Ishigami F, Hakomori S, Shevinsky LH, Knowles BB and Solter D (1983) New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. J Biol Chem 258, 8934-8942.
Kolter T, Proia RL and Sandhoff K (2002) Combinatorial ganglioside biosynthesis. J Biol Chem 277, 25859-25862.
Furukawa K, Takamiya K and Furukawa K (2002) Beta 1,4-N-acetylgalactosaminyltransferase-GM2/GD2 synthase: a key enzyme to control the synthesis of brain-enriched complex gangliosides. Biochim Biophys Acta 1573, 356-362.
Kimber SJ, Brown DG, Pahlsson P and Nilsson B (1993) Carbohydrate antigen expression in murine embryonic stem cells and embryos. II. Sialylated antigens and glycolipid analysis. Histochem J 25, 628-641.
Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K and Proia RL (1999) A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci USA 96, 9142-9147.
Kwak DH, Yu K, Kim SM, Lee DH, Kim SM, Jung JU, Seo JW, Kim N, Lee S, Jung KY et al. (2006) Dynamic changes of gangliosides expression during the differentiation of embryonic and mesenchymal stem cells into neural cells. Exp Mol Med 38, 668-676.
Lee DH, Koo DB, Ko K, Ko K, Kim SM, Jung JU, Ryu JS, Jin JW, Yang HJ, Do SI et al. (2007) Effects of daunorubicin on ganglioside expression and neuronal differentiation of mouse embryonic stem cells. Biochem Biophys Res Commun 362, 313-318.
Jung JU, Ko K, Lee DH, Ko K, Chang KT and Choo YK (2009) The roles of glycosphingolipids in the proliferation and neural differentiation of mouse embryonic stem cells. Exp Mol Med 41, 935-945.
Hakomori SI (2008) Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Biochim Biophys Acta 1780, 325-346.
Yu RK, Macala LJ, Taki T, Weinfield HM and Yu FS (1988) Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J Neurochem 50, 1825-1829.
Hakomori SI (2000) Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J 17, 143-151.
Turley EA, Veiseh M, Radisky DC and Bissell MJ (2008) Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 5, 280-290.
Thiery JP, Acloque H, Huang RY and Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
Hay ED (2005) The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 233, 706-720.
Kalluri R and Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420-1428.
Guan F, Schaffer L, Handa K and Hakomori S (2010) Functional role of gangliotetraosylceramide in epithelial-to-mesenchymal transition process induced by hypoxia and by TGF-beta. Faseb J 24, 4889-4903.
Guan F, Handa K and Hakomori S (2009) Specific glycosphingolipids mediate epithelial-to-mesenchymal transition of human and mouse epithelial cell lines. Proc Natl Acad Sci USA 106, 7461-7466.
Kim SJ, Chung TW, Choi HJ, Kwak CH, Song KH, Suh SJ, Kwon KM, Chang YC, Park YG, Chang HW et al. (2013) Ganglioside GM3 participates in the TGF-beta1-induced epithelial-mesenchymal transition of human lens epithelial cells. Biochem J 449, 241-251.
Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC and Weinberg RA (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15, 50-65.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M et al. (2010) Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28, 1435-1445.
Liang YJ, Ding Y, Levery SB, Lobaton M, Handa K and Hakomori SI (2013) Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci USA 110, 4968-4973.
Takahashi K and Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
Squadrito ML, Cianciaruso C, Hansen SK and De Palma M (2018) EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat Methods 15, 183-186.
Svennerholm L, Bostrom K, Fredman P, Jungbjer B, Lekman A, Mansson JE and Rynmark BM (1994) Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1214, 115-123.
Yuki N, Yamada M, Tagawa Y, Takahashi H and Handa S (1997) Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci 149, 127-130.
Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK and Reisfeld RA (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44, 5914-5920.
Tsuchida T, Saxton RE, Morton DL and Irie RF (1987) Gangliosides of human melanoma. J Natl Cancer Inst 78, 45-54.
Wu ZL, Schwartz E, Seeger R and Ladisch S (1986) Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 46, 440-443.
Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH and Cheung NK (1987) Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 47, 5377-5381.
Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G et al. (2012) Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Investig 122, 2066-2078.
Lin JJ, Huang CS, Yu J, Liao GS, Lien HC, Hung JT, Lin RJ, Chou FP, Yeh KT and Yu AL (2014) Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells. Breast Cancer Res 16, R29.
Yanagisawa M, Yoshimura S and Yu RK (2011) Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN Neuro 3, e00054.
Martinez C, Hofmann TJ, Marino R, Dominici M and Horwitz EM (2007) Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 109, 4245-4258.
Jin HJ, Nam HY, Bae YK, Kim SY, Im IR, Oh W, Yang YS, Choi SJ and Kim SW (2010) GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells. Cell Mol Life Sci 67, 1845-1858.
Klassen H, Schwartz MR, Bailey AH and Young MJ (2001) Surface markers expressed by multipotent human and mouse neural progenitor cells include tetraspanins and non-protein epitopes. Neurosci Lett 312, 180-182.
Xu J, Fan W, Tu XX, Zhang T, Hou ZJ, Guo T, Shu X, Luo X, Liu Y, Peng F et al. (2013) Neural ganglioside GD2(+) cells define a subpopulation of mesenchymal stem cells in adult murine bone marrow. Cell Physiol Biochem 32, 889-898.
Woo SR, Oh YT, An JY, Kang BG, Nam DH and Joo KM (2015) Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness. Anat Cell Biol 48, 44-53.
Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, Do KA, Ueno NT, Andreeff M and Battula VL (2018) ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway. Mol Cancer Ther 17, 2689-2701.
Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A, Tutt A, Tulasne D, Le Bourhis X and Delannoy P (2010) GD(3) synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res 8, 1526-1535.
Kang NY, Kang SK, Lee YC, Choi HJ, Lee YS, Cho SY, Kim YS, Ko JH and Kim CH (2006) Transcriptional regulation of the human GD3 synthase gene expression in Fas-induced Jurkat T cells: a critical role of transcription factor NF-kappaB in regulated expression. Glycobiology 16, 375-389.
Miyata M, Ichihara M, Tajima O, Sobue S, Kambe M, Sugiura K, Furukawa K and Furukawa K (2014) UVB-irradiated keratinocytes induce melanoma-associated ganglioside GD3 synthase gene in melanocytes via secretion of tumor necrosis factor alpha and interleukin 6. Biochem Biophys Res Commun 445, 504-510.
Bobowski M, Vincent A, Steenackers A, Colomb F, Van Seuningen I, Julien S and Delannoy P (2013) Estradiol represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFkappaB binding to ST8SIA1 promoter. PLoS One 8, e62559.
Li RX and Ladisch S (1991) Shedding of human neuroblastoma gangliosides. Biochim Biophys Acta 1083, 57-64.
Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky C and Seeger R (1987) Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 39, 73-76.
Biswas S, Biswas K, Richmond A, Ko J, Ghosh S, Simmons M, Rayman P, Rini B, Gill I, Tannenbaum CS et al. (2009) Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol 183, 5050-5058.
Chen YX, Chen XW, Li CG, Yue LJ, Mai HR and Wen FQ (2013) Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen. Oncol Rep 29, 343-348.
Doronin II, Vishnyakova PA, Kholodenko IV, Ponomarev ED, Ryazantsev DY, Molotkovskaya IM and Kholodenko RV (2014) Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer 14, 295.
Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D and Rokita H (2009) The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett 281, 171-182.
Horwacik I, Durbas M, Boratyn E, Wegrzyn P and Rokita H (2013) Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett 341, 248-264.
Durbas M, Horwacik I, Boratyn E, Kamycka E and Rokita H (2015) GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines. Int J Oncol 47, 1143-1159.
Horwacik I, Durbas M, Boratyn E, Sawicka A, Wegrzyn P, Krzanik S, Gorka A, Drozniak J, Augustyniak E, Kowalczyk A et al. (2015) Analysis of genes involved in response to doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal antibody in IMR-32 human neuroblastoma cells. Acta Biochim Pol 62, 423-433.
Liu B, Wu Y, Zhou Y and Peng D (2014) Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells. PLoS One 9, e93576.
Tsao CY, Sabbatino F, Cheung NV, Hsu JC, Villani V, Wang X and Ferrone S (2015) Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. Oncoimmunology 4, e1023975.
Tong W, Maira M, Gagnon M and Saragovi HU (2015) Ligands binding to cell surface ganglioside GD2 cause Src-dependent activation of N-Methyl-D-aspartate receptor signaling and changes in cellular morphology. PLoS One 10, e0134255.
Villanueva-Cabello TM, Mollicone R, Cruz-Munoz ME, Lopez-Guerrero DV and Martinez-Duncker I (2015) Activation of human naive Th cells increases surface expression of GD3 and induces neoexpression of GD2 that colocalize with TCR clusters. Glycobiology 25, 1454-1464.
Nagafuku M, Okuyama K, Onimaru Y, Suzuki A, Odagiri Y, Yamashita T, Iwasaki K, Fujiwara M, Takayanagi M, Ohno I et al. (2012) CD4 and CD8 T cells require different membrane gangliosides for activation. Proc Natl Acad Sci USA 109, E336-E342.
Reddig PJ and Juliano RL (2005) Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 24, 425-439.
Cheresh DA, Harper JR, Schulz G and Reisfeld RA (1984) Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81, 5767-5771.
Ohmi Y, Kambe M, Ohkawa Y, Hamamura K, Tajima O, Takeuchi R, Furukawa K and Furukawa K (2018) Differential roles of gangliosides in malignant properties of melanomas. PLoS One 13, e0206881.
Astronomo RD and Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9, 308-324.
Dube DH and Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4, 477-488.
Huang C-S, Yu AL, Tseng L-M, Chow LWC, Hou M-F, Hurvitz SA, Schwab RB, Murray JL, Chang H-K, Chang H-T et al. (2019) Globo H-KLH vaccine AS/OBI-821 in patients with metastatic 1 breast cancer: phase II randomized, placebo-controlled study. J ImmunoTher Cancer 8, e000342.
Padro M, Mejias-Luque R, Cobler L, Garrido M, Perez-Garay M, Puig S, Peracaula R and de Bolos C (2011) Regulation of glycosyltransferases and Lewis antigens expression by IL-1beta and IL-6 in human gastric cancer cells. Glycoconjugate J 28, 99-110.
Taniuchi F, Higai K, Tanaka T, Azuma Y and Matsumoto K (2013) Transcriptional regulation of fucosyltransferase 1 gene expression in colon cancer cells. ScientificWorldJournal. 2013, 105464.
Cai BH, Lee HY, Chou CK, Wu PH, Huang HC, Chao CC, Chung HY and Kannagi R (2020) SSEA3 and sialyl lewis a glycan expression is controlled by B3GALT5 LTR through Lamin A-NFYA and SIRT1-STAT3 signaling in human ES cells. Cells 9, 177.
Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3, e3077.
Suzuki Y, Haraguchi N, Takahashi H, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Ishii H, Doki Y et al. (2013) SSEA-3 as a novel amplifying cancer cell surface marker in colorectal cancers. Int J Oncol 42, 161-167.
Aisiku OR, Runnels LW and Scarlata S (2010) Identification of a novel binding partner of phospholipase cβ1: translin-associated factor X. PLoS One 5, e15001.
Wang SH, Lee AC, Chen IJ, Chang NC, Wu HC, Yu HM, Chang YJ, Lee TW, Yu JC, Yu AL et al. (2016) Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy. Biomaterials 94, 31-44.
Mujoo K, Cheresh DA, Yang HM and Reisfeld RA (1987) Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 47, 1098-1104.
Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ and Reisfeld RA (1989) Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 49, 2857-2561.
Uttenreuther-Fischer MM, Huang CS, Reisfeld RA and Yu AL (1995) Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother 41, 29-36.
Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS et al. (1994) Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12, 184-193.
Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH et al. (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52, 4342-4347.
Saito M, Yu RK and Cheung NK (1985) Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun 127, 1-7.
Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF and Berger NA (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5, 1430-1440.
Cheung NK, Kushner BH, Yeh SD and Larson SM (1998) 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol 12, 1299-1306.
Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Kramer K, Modak S, Yataghene K and Cheung NK (2015) Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study. Oncoimmunology 4, e1016704.
Miraldi FD, Nelson AD, Kraly C, Ellery S, Landmeier B, Coccia PF, Strandjord SE and Cheung NK (1986) Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161, 413-418.
Cheung NK, Landmeier B, Neely J, Nelson AD, Abramowsky C, Ellery S, Adams RB and Miraldi F (1986) Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 77, 739-745.
Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD et al. (2007) Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 25, 5465-5470.
Gillies SD, Lo KM and Wesolowski J (1989) High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Method 125, 191-202.
Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R and Lode HN (2005) Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42, 1311-1319.
Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL and Reisfeld RA (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51, 144-149.
Mueller BM, Romerdahl CA, Gillies SD and Reisfeld RA (1990) Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 144, 1382-1386.
Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA and Neithammer D (1995) A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A, 261-267.
Uttenreuther-Fischer MM, Huang CS and Yu AL (1995) Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother 41, 331-338.
Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA and Kung FH (1998) Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16, 2169-2180.
Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH and Seeger RC (2000) Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 18, 4077-4085.
Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH et al. (2009) Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 27, 85-91.
Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP et al. (2018) A Comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin In High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol 9, 1355.
Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C et al. (2018) Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 19, 1617-1629.
Belounis A, Ayoub M, Cordeiro P, Lemieux W, Teira P, Haddad E, Herblot S and Duval M. (2020) Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing. Cancer Immunol Immunother 69, 1767-1779.
Wu HW, Sheard MA, Malvar J, Fernandez GE, DeClerck YA, Blavier L, Shimada H, Theuer CP, Sposto R and Seeger RC (2019) Anti-CD105 antibody eliminates tumor microenvironment cells and enhances Anti-GD2 antibody immunotherapy of neuroblastoma with activated natural killer cells. Clin Cancer Res 25, 4761-4774.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM et al. (2017) Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol 18, 946-957.
Sorkin LS, Otto M, Baldwin WM 3rd, Vail E, Gillies SD, Handgretinger R, Barfield RC, Ming Yu, Yu HM and Yu AL (2010) Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 149, 135-142.
Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K et al. (2014) Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 32, 1445-1452.
Furman WL, Federico SM, McCarville MB, Shulkin BL, Davidoff AM, Krasin MJ, Sahr N, Sykes A, Wu J, Brennan RC et al. (2019) A Phase II Trial of Hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma. Clin Cancer Res 25, 6320-6328.
Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, Servaes S, London WB, Shimada H, Gan J et al. (2019) Antitumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: a children's oncology group phase II study. Clin Cancer Res 25, 6044-6051.
Cheung NK, Guo H, Hu J, Tassev DV and Cheung IY (2012) Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 1, 477-486.
Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS and Cheung NK (2018) Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial. JAMA Oncol 4, 1729-1735.
Zhao Q, Ahmed M, Guo HF, Cheung IY and Cheung NK (2015) Alteration of electrostatic surface potential enhances affinity and tumor killing properties of anti-ganglioside GD2 monoclonal antibody hu3F8. The J Biol Chem 290, 13017-13027.
Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR et al. (2007) Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 13, 4170-4177.
Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L et al. (1999) Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci USA 96, 5710-5715.
Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bornmann WG, Spassova M, Bencsath KP, Panageas KS et al. (2001) Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci USA 98, 3270-3275.
Rugo HS. (2020). Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence, ASCO Virtual Scientific Program.
Tsimberidou AM. (2020). A first-in-man phase I/II study of OBI-3424, an AKR1C3-selective bis-alkylating agent prodrug, in subjects with advanced cancer, including hepatocellular carcinoma (HCC) and castrate-resistant prostate cancer (CRPC), ASCO Virtual Scientific Program. J Clin Oncol 38 (15_suppl), TPS3658.
Tsimberidou AM. (2020). A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors, ASCO Virtual Scientific Program. J Clin Oncol 38 (15_suppl), TPS3657.
Huang YL, Hung JT, Cheung SK, Lee HY, Chu KC, Li ST, Lin YC, Ren CT, Cheng TJ, Hsu TL et al. (2013) Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc Natl Acad Sci USA 110, 2517-2522.